Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Metastatic NSCLC
NCT03057106Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 2017
- Primary completion
- Feb 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by Canadian Cancer Trials Group. Started Mar 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03057106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057106.